INO-4800

Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return over the last 12 months is 29.2%. But there is no question some big-name stocks performed better than others along the way. Inovio’s Bumpy Road:...

Despite Inovio Pharmaceuticals Inc's (NASDAQ: INO) first-quarter miss Monday, the sell-side remains largely upbeat on company, which is developing a coronavirus vaccine candidate.  The Inovio Analysts Stifel analyst Stephen Wiley maintained a Buy rating and $19 price target for Inovio...